Paroxysmal Nocturnal Hemoglobinuria (PNH)
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy
Patients with paroxysmal nocturnal hemoglobinuria
Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry
Ravulizumab, a second-generation complement component 5 inhibitor (C5i) derived from eculizumab eculizumab:
2026 New Brunswick Patient and Family Conference
CONFERENCE LOCATION:
Jack & Sheryl Morris Cancer Center
165 Somerset Street
New Brunswick, NJ 08901
PARKING:
There are two free parking options:
Valet Parking: Available at 15 Division Street, New Brunswick.
Self-Parking: Available in the Hardenberg Street Garage (18 Hardenberg Street, New Brunswick). Take the third-floor skybridge directly into the Cancer Center
Cord Blood Transplant
Topic(s)
Bone Marrow Transplant
Presenter(s)
Filippo Milano, MD, PhD
During this webinar, Dr. Filippo Milano will discuss cord blood transplant and its role in treating blood cancers and hematological disorders. He will discuss the unique benefits of cord blood as a stem cell source, recent advances in transplantation techniques, and strategies to…
Long-term outcomes of patients surviving beyond 2 years post–allogeneic stem cell transplantation.
Original Publication Date
Article Source
External Web Content
Abstract 6508 Background: Advances in hematopoietic stem cell transplantation (HSCT) have been driven by progress in supportive care, conditioning regimens, and graft-versus-host disease (GvHD) prophylaxis. Post-transplant morbidity and mortality are most pronounced in the first…
Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis
Original Publication Date
Article Source
External Web Content
Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-Cy) has become an established alternative for patients lacking HLA-matched donors, with outcomes comparable to those of matched-sibling and unrelated-donor transplants [1]. While CD34…
Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT: a 20-year single-center experience
Original Publication Date
Article Source
External Web Content
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) clones are detected in up to 60% of patients with aplastic anemia (AA); however, their prognostic impact remains incompletely defined, particularly in the context of frontline immunosuppressive therapy (IST) or…
Haploidentical allogeneic haematopoietic stem cell transplantation for paroxysmal nocturnal haemoglobinuria: a retrospective analysis
Original Publication Date
Article Source
External Web Content
Abstract Objective: To evaluate the efficacy and prognostic factors of haploidentical haematopoietic stem cell transplantation (haplo-HSCT) for paroxysmal nocturnal haemoglobinuria (PNH). Methods: We retrospectively analyzed 36 PNH patients (2 classic PNH, 34 AA-PNH syndrome)…
Clonal Signatures of Telomere Biology Disorders
Original Publication Date
Article Source
External Web Content
Abstract Purpose of Review In inherited bone marrow failure syndromes (IBMFS), clonal hematopoiesis (CH) has been increasingly recognized as a molecular fingerprint of the underlying pathophysiology. A specific clonal profile has been reported in telomere biology disorders (TBDs)…